IP Library Granted Patent US 9,321,996
Granted Patent B2
US 9,321,996 · App. 13/608,803 · Granted Apr 26, 2016

Serum-free mammalian cell culture medium, and uses thereof

Inventors: Stephen Gorfien (Williamsville, NY); Richard Fike (Clarence, NY); Glenn Godwin (Holbrook, MA); Joyce Dzimian (Lancaster, NY); David Epstein (East Amherst, NY); Dale Gruber (Leesburg, FL); Don McClure (Indianapolis, IN); Paul Price (Mount Pleasant, SC)
Assignee: Life Technologies Corporation
C12N5/0682C07K14/61C12N5/005C12N5/0037C12N5/0043C12N5/0603C12N7/00C12N9/2402C12N9/2471C12N15/85C12Y302/01023C12N2500/14C12N2500/16C12N2500/22C12N2500/24C12N2500/32C12N2500/34C12N2500/35C12N2500/38C12N2500/74C12N2500/76C12N2500/90C12N2500/95C12N2501/90C12N2501/91C12N2710/10051
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,321,996
App. No.
13/608,803
Granted
Apr 26, 2016
Kind
B2
Abstract

The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate. The present invention also provides chemically defined, protein-free eukaryotic cell culture media comprising an iron chelate and zinc, which is capable of supporting the growth (and particularly the high-density growth of mammalian cells) in suspension culture, increasing the level of expression of recombinant protein in cultured cells, and/or increasing virus production in cultured cells.

Claims (19)

1. A method of producing a recombinant polypeptide or a viral protein in vitro, comprising: culturing a recombinant CHO cell in suspension in a serum-free and protein-free cell culture medium, under conditions suitable for the expression of said polypeptide, or viral protein, wherein the medium comprises a transferrin substitute and an insulin substitute and supports increased CHO cell growth in suspension as compared to culture in FMX-8 medium, wherein said transferrin substitute comprises iron or an iron containing compound and said insulin substitute comprises zinc or a zinc containing compound, wherein said cell suspension culture is without supplementation of serum and without supplementation of protein, and wherein the cultivation of the CHO cell does not require that the CHO cell express an exogenous recombinant protein.

2. The method of producing the recombinant polypeptide or the viral protein in vitro of claim 1 wherein the recombinant polypeptide is a secreted protein.

3. The method of producing the recombinant polypeptide or the viral protein in vitro of claim 1 wherein the recombinant polypeptide or the viral protein is harvested from the used cell culture medium.

4. The method of producing the recombinant polypeptide or the viral protein in vitro of claim 3 wherein the recombinant polypeptide or the viral protein is isolated.

5. A system for culturing a CHO cell producing a recombinant polypeptide or a viral protein in vitro comprising:

i. a serum free and protein free medium comprising a transferrin substitute and an insulin substitute;

ii. the CHO cell;

iii. a bioreactor;

wherein said medium supports increased CHO cell growth in suspension as compared to culture in FMX-8 medium without supplementation of serum and without supplementation of protein, and without the expression of an exogenous recombinant protein for CHO cell cultivation, and

wherein said transferrin substitute comprises iron or an iron containing compound and said insulin substitute comprises zinc or a zinc containing compound.

6. The system for culturing the CHO cell in vitro of claim 5 wherein said CHO cell is cultivated under conditions favoring the expression of the recombinant protein or the virus.

7. The system for culturing the CHO cell in vitro of claim 6 wherein said CHO cell expresses the recombinant protein or the virus.

8. The system for culturing the CHO cell in vitro of claim 6 wherein said recombinant protein is a secreted protein.

9. The system for culturing the CHO cell in vitro of claim 7 wherein the recombinant polypeptide or the viral protein is harvested from the used cell culture medium.

10. The system for culturing the CHO cell in vitro of claim 9 wherein the recombinant polypeptide or the viral protein is isolated.

11. The system for culturing the CHO cell in vitro of claim 5 wherein said CHO cell is cultivated on a microcarrier or a bead.

12. The system for culturing the CHO cell in vitro of claim 5 wherein said system is capable of supporting high-density growth of the CHO cell in suspension.

13. The system for culturing the CHO cell in vitro of claim 12 wherein said high-density growth is at least about 1.0×10 6 to 2.0×10 7 cells/ml.

14. The system for culturing the CHO cell in vitro of claim 5 wherein the bioreactor is supplemented with nutrients on day nine.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2015
From: GORFIEN, STEPHEN F.; FIKE, RICHARD M.; DZIMIAN, JOYCE L.; GODWIN, GLENN P.; PRICE, PAUL J.; EPSTEIN, DAVID A.; GRUBER, DALE
To: LIFE TECHNOLOGIES, INC.
Reel/Frame 037206/0160 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2015
From: MCCLURE, DON
To: ELI LILLY AND COMPANY
Reel/Frame 037206/0172 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2015
From: ELI LILLY AND COMPANY
To: LIFE TECHNOLOGIES, INC.
Reel/Frame 037206/0176 →
MERGER Recorded Dec 3, 2015
From: LIFE TECHNOLOGIES, INC.
To: INVITROGEN CORPORATION
Reel/Frame 037206/0189 →
MERGER Recorded Dec 3, 2015
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 037206/0216 →
Priority Claims (1)
WO PCT/US97/15926 · Sep 9, 1997 · international
Continuity (7)
Division 12463351 · May 8, 2009
Continuation 11151647 · Jun 14, 2005
Continuation 09028514 · Feb 23, 1998
Continuation In Part 08920875 · Aug 29, 1997
Provisional Application 60056829 · Aug 22, 1997
Provisional Application 60022881 · Aug 30, 1996
Related Publication 20130065275A1 · Mar 14, 2013